Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment.
PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.
|Official Title:||Identification of Target Genes for Diagnosis and Prognosis of AML Using a Custom-Design Microarray|
- Correlation of increased or decreased expression of same transcripts with disease outcome [ Designated as safety issue: No ]
- Minimum number of genes that can be used for precise diagnosis of each of the three subtypes of acute myeloid leukemia [ Designated as safety issue: No ]
- Identification of individual genes that are differentially expressed between the subtypes of AMLs [ Designated as safety issue: No ]
- Correlation of the patterns of expression of the translocation-specific transcripts with age, sex, race, response to treatment, survival, and with other known mutations [ Designated as safety issue: No ]
|Study Start Date:||May 2008|
|Estimated Primary Completion Date:||May 2009 (Final data collection date for primary outcome measure)|
- To identify and validate individual genes for diagnosis of three major translocations in acute myeloid leukemia.
- To correlate transcript expression data in the various translocations with age, sex, race, response to treatment, and survival and with other known mutations.
OUTLINE: Blood and/or bone marrow samples previously procured from patients on CALGB-9665 are obtained from the CALGB Leukemia Tissue Bank from patients enrolled on CALGB AML treatment studies. Mononuclear cells are isolated from samples and mRNA is extracted. Gene expression profiles are analyzed via custom mRNA microarray and confirmed by quantitative real-time PCR.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00897182
|United States, Indiana|
|Fort Wayne Medical Oncology and Hematology|
|Fort Wayne, Indiana, United States, 46845|
|United States, North Carolina|
|Wayne Memorial Hospital, Incorporated|
|Goldsboro, North Carolina, United States, 27534|
|Study Chair:||Janet Rowley, MD||University of Chicago|